ArticleJournal of applied clinical medical physics2025
Novel CT radiomics models for the postoperative prediction of early recurrence of resectable pancreatic adenocarcinoma: A single-center retrospective study in China.
Article in Journal of applied clinical medical physics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Novel CT radiomics models for the postoperative prediction of early recurrence of resectable pancreatic adenocarcinoma: A single-center retrospective study in China.Journal of applied clinical medical physics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo assess the predictive capability of CT radiomics features for early recurrence (ER) of pancreatic ductal adenocarcinoma (PDAC).
methodsPostoperative PDAC patients were retrospectively selected, all of whom had undergone preoperative CT imaging and surgery. Both patients with resectable or borderline-resectable pancreatic cancer met the eligibility criteria in this study. However, owing to the differences in treatment strategies and such, this research mainly focused on patients with resectable pancreatic cancer. All patients were subject to follow-up assessments for a minimum of 9 months. A total of 250 cases meeting the inclusion criteria were included. A clinical model, a conventional radiomics model, and a deep-radiomics model were constructed for ER prediction (defined as occurring within 9 months) in the training set. A model based on the TNM staging was utilized as a baseline for comparison. Assessment of the models' performance was based on the area under the receiver operating characteristic curve (AUC). Additionally, precision-recall (PR) analysis and calibration assessments were conducted for model evaluation. Furthermore, the clinical utility of the models was evaluated through decision curve analysis (DCA), net reclassification improvement (NRI), and improvement of reclassification index (IRI).
resultsIn the test set, the AUC values for ER prediction were as follows: TNM staging, ROC-AUC = 0.673 (95% CI: 0.550, 0.795), PR-AUC = 0.362 (95% CI: 0.493, 0.710); clinical model, ROC-AUC = 0.640 (95% CI: 0.504, 0.775), PR-AUC = 0.481 (95% CI: 0.520, 0.735); radiomics model, ROC-AUC = 0.722 (95% CI: 0.604, 0.839), PR-AUC = 0.575 (95% CI: 0.466, 0.686); and deep-radiomics model, which exhibited the highest ROC-AUC of 0.895 (95% CI: 0.820, 0.970), PR-AUC = 0.834 (95% CI: 0.767, 0.923). The difference in both ROC-AUC and PR-AUC for the deep-radiomics model was statistically significant when compared to the other scores (all p < 0.05). The DCA curve of the deep-radiomics model outperformed the other models. NRI and IRI analyses demonstrated that the deep-radiomics model significantly enhances risk classification compared to the other prediction methods (all p < 0.05).
conclusionThe predictive performance of deep features based on CT images exhibits favorable outcomes in predicting early recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.